People · Operator
Named in public records as an officer, director or promoter · active 2016–2022 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Renovion, Inc. | — | Pharmaceuticals | Series B | $25.8M | $192.1M | 2016 |
Daniel W. Copeland at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Daniel W. Copeland on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| R. Frederick McCoy, Jr. | 1 | 3 |
| THOMAS U. BARTON | 1 | 2 |
| Joseph W. Davis | 1 | 1 |
| Derek Frederick Winstanly | 1 | 1 |
| DEREK W. WINSTANLY | 1 | 1 |
| RICHARD W. MATTINGLY | 1 | 1 |
| JON W. CIVITARESE | 1 | 1 |
| ROBERT FREDERICK RYAN | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.